Market Research Logo

Global Human Microbiome Market Forecast 2018-2022

Global Human Microbiome Market Forecast 2018-2022

KEY FINDINGS

Driven by the rising prevalence of chronic diseases, focus on early disease detection and diagnosis and growing prevalence of precision medicines, the global human microbiome market is anticipated to exhibit a CAGR of 22.41% between 2022-2026.

MARKET INSIGHTS

The global human microbiome market is segmented on the basis of products, applications, and diseases. The product segment is categorized into Foods, Probiotics, Prebiotics, Medical foods, Drugs, Diagnostic device, and other products. The application segment of the market includes diagnostics and drugs while the Diseases segment includes Obesity, Cancer,Type 2 diabetes, Crohn’s disease, Ulcerative colitis, C. Difficle infection, Dental caries, Lactose intolerance, Recurrent bacterial vaginosis and UTI, Hyperoxaluria, Skin disorders,Celiac disease, Phenylketonuria, Urea cycle disorder, Hepatic encephalopathy and Non-alcoholic Steatohepatitis.

REGIONAL INSIGHTS

Regionally, the market is segmented into Asia-Pacific, Europe, North America and rest of the world. By the end of 2026, the North American market is anticipated to dominate the global scene owing to the massive on-going research and increasing funding by several private companies and research institutes. Leading this region is the United States human microbiome market, which is home to several market giants. However, the Asia-Pacific human microbiome market is exhibiting a surging trend, boosted by the heavy funding in the region. China and Japan are at the forefront of this region, and these countries have undertaken several initiatives to augment the methods for the assessment of various biological phenomenon by standardizing various procedures and protocols.

COMPETITIVE INSIGHTS

Few of the well-known companies engaged in the global human microbiome market include Avidbiotics Inc., 4d Pharma, Actogenix Nv (Acquired By Intrexon Corporation), Enterome Sa, Avidbiotics Corp, Metabiomics, Metabogen Ab, Microbiome Therapeutics, Miomics, Rebiotix, Osel Inc, Ritter Pharmaceuticals Inc, Symberix Inc, Second Genome, Symbiotix Biotherapies Inc, and Vedanta Biosciences Inc.(Acquired By Puretech Health Plc).


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. North America Is The Global Leader In Human Microbiome Market
3.2.2. Probiotics Product Are Majorly Used
3.2.3. Use Of Personalized Medicines Is Increasing
4. Market Determinants
4.1. Market Drivers
4.1.1. Rising Prevalence Of Precision Medicines
4.1.2. Focus On Early Disease Detection And Diagnosis
4.1.3. Growing Prevalence Of Chronic Diseases
4.2. Market Restraints
4.2.1. Barriers In Early Detection And Diagnosis
4.2.2. Lack Of Technological Expertise
4.2.3. Lack Of Skilled Professionals And Lack Of Proper Infrastructure In Microbiome Stream
4.2.4. Stringent Government Regulations
4.3. Market Opportunities
4.3.1. Increasing Investment In Novel Drugs
4.3.2. Growing Investment In R&D
4.3.3. Increase In Lifestyle Diseases Are Expected To Drive The Demand For New And Advanced Drugs
4.3.4. Rapidly Changing Lifestyle In The Emerging Countries
4.4. Market Challenges
4.4.1. Lack Of Awareness
4.4.2. New Technology Barrier To Enter Into The Market
5. Market Segmentation
5.1. Market By Applications 2018-2026
5.1.1. Drugs
5.1.2. Diagnostics
5.2. Market By Products 2018-2026
5.2.1. Probiotics
5.2.2. Foods
5.2.3. Prebiotics
5.2.4. Medical Foods
5.2.5. Diagnostic Device
5.2.6. Drugs
5.2.7. Other Products
5.3. Market By Diseases 2018-2026
5.3.1. Cancer
5.3.2. Obesity
5.3.3. Type 2 Diabetes
5.3.4. Ulcerative Colitis
5.3.5. Crohn’s Disease
5.3.6. C. Difficle Infection
5.3.7. Lactose Intolerance
5.3.8. Dental Caries
5.3.9. Recurrent Bacterial Vaginosis And Uti
5.3.10. Skin Disorders
5.3.11. Hyperoxaluria
5.3.12. Celiac Disease
5.3.13. Urea Cycle Disorder
5.3.14. Phenylketonuria
5.3.15. Non-alcoholic Steatohepatitis
5.3.16. Hepatic Encephalopathy
6. Key Analytics
6.1. Porter’s 5 Forces Analysis
6.1.1. Threat Of New Entrants
6.1.2. Threat Of Substitute Products Or Services
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Advances In Microbiome Research
6.3. Area Of Focus For Microbiome Based Drugs And Diagnostics
6.4. Supply Chain Analysis
6.5. Key Buying Criteria
6.6. Regulatory Framework
6.7. Product Development Strategies
6.8. Estimation Analysis
6.9. Challenges In Microbiome Drug Development
6.10. Parent Market Analysis
6.11. Products In Pipeline
6.12. Intellectual Property, Investments And Collaborations
6.12.1. Intellectual Property
6.12.2. Investments And Collaborations
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Italy
7.2.5. Spain
7.2.6. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. South Korea
7.3.5. Australia
7.3.6. Rest Of Apac
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East & Africa
8. Company Profiles
8.1. Competitive Landscape
8.1.1. Market Share Analysis
8.2. 4d Pharma
8.2.1. Company Overview
8.2.2. Product Portfolio
8.3. Avidbiotics Inc.
8.3.1. Company Overview
8.3.2. Product Portfolio
8.4. Actogenix Nv (Acquired By Intrexon Corporation)
8.4.1. Company Overview
8.4.2. Product Portfolio
8.4.3. Scot Analysis
8.4.4. Strategic Initiatives
8.5. Avidbiotics Corp.
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Scot Analysis
8.5.4. Strategic Initiatives
8.6. Enterome Sa
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Scot Analysis
8.6.4. Strategic Initiatives
8.7. Metabiomics
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Scot Analysis
8.7.4. Strategic Moves
8.8. Microbiome Therapeutics
8.8.1. Company Overview
8.8.2. Product Portfolio
8.8.3. Scot Analysis
8.8.4. Strategic Moves
8.9. Metabogen Ab
8.9.1. Company Overview
8.9.2. Product Portfolio
8.9.3. Scot Analysis
8.9.4. Strategic Initiatives
8.10. Miomics
8.10.1. Company Overview
8.10.2. Product Portfolio
8.10.3. Scot Analysis
8.11. Osel Inc
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.3. Scot Analysis
8.12. Rebiotix
8.12.1. Company Overview
8.12.2. Product Portfolio
8.12.3. Scot Analysis
8.12.4. Strategic Initiatives
8.13. Ritter Pharmaceuticals, Inc
8.13.1. Company Overview
8.13.2. Product Portfolio
8.13.3. Scot Analysis
8.13.4. Strategic Initiatives
8.14. Second Genome
8.14.1. Company Overview
8.14.2. Scot Analysis
8.14.3. Strategic Initiatives
8.15. Symberix Inc
8.15.1. Company Overview
8.15.2. Product Portfolio
8.15.3. Scot Analysis
8.16. Symbiotix Biotherapies, Inc.
8.16.1. Company Overview
8.16.2. Product Portfolio
8.16.3. Scot Analysis
8.16.4. Strategic Initiatives
8.17. Vedanta Biosciences, Inc.(Acquired By Puretech Health Plc)
8.17.1. Company Overview
8.17.2. Product Portfolio
8.17.3. Scot Analysis
8.17.4. Strategic Initiatives
Table List
Table 1 Global Human Microbiome Market By Geography 2018-2022 ($ Million)
Table 2 Global Human Microbiome Market By Geography 2022-2026 ($ Million)
Table 3 Incidence Of Diabetes In The Major Countries In 2016(Millions)
Table 4 Companies Working Towards Developing New Drugs
Table 5 Global Human Microbiome Market By Applications 2018-2022 ($ Million)
Table 6 Global Human Microbiome Market By Applications 2022-2026 ($ Million)
Table 7 Global Human Microbiome Market By Products 2018-2022 ($ Million)
Table 8 Global Human Microbiome Market By Products 2022-2026 ($ Million)
Table 9 Global Human Microbiome Market In Probiotics By Geography 2018-2022 ($ Million)
Table 10 Global Human Microbiome Market In Probiotics By Geography 2022-2026 ($ Million)
Table 11 Global Human Microbiome Market In Foods By Geography 2018-2022 ($ Million)
Table 12 Global Human Microbiome Market In Foods By Geography 2022-2026 ($ Million)
Table 13 Global Human Microbiome Market In Prebiotics By Geography 2018-2022 ($ Million)
Table 14 Global Human Microbiome Market In Prebiotics By Geography 2022-2026 ($ Million)
Table 15 Global Human Microbiome Market In Medical Foods By Geography 2018-2022 ($ Million)
Table 16 Global Human Microbiome Market In Medical Foods By Geography 2022-2026 ($ Million)
Table 17 Global Human Microbiome Market In Diagnostic Device By Geography 2018-2022 ($ Million)
Table 18 Global Human Microbiome Market In Diagnostic Device By Geography 2022-2026 ($ Million)
Table 19 Global Human Microbiome Market In Drugs By Geography 2018-2022 ($ Million)
Table 20 Global Human Microbiome Market In Drugs By Geography 2022-2026 ($ Million)
Table 21 Global Human Microbiome Market In Other Products By Geography 2018-2022 ($ Million)
Table 22 Global Human Microbiome Market In Other Products By Geography 2022-2026 ($ Million)
Table 23 Global Human Microbiome Market By Diseases 2018-2022 ($ Million)
Table 24 Global Human Microbiome Market By Diseases 2022-2026 ($ Million)
Table 25 Microbiota Associated With Cancers
Table 26 Microbiome-based Drugs In Development For Cancer
Table 27 Microbiota Associated With Obesity
Table 28 Microbiome-based Drugs In Development For Obesity
Table 29 Microbiota Associated With Type 2 Diabetes
Table 30 Microbiome-based Drugs In Development For Type 2 Diabetes
Table 31 Microbiome-based Drugs In Development For Ulcerative Colitis
Table 32 Microbiome-based Drugs In Development For Crohn’s Disease
Table 33 Microbiome-based Drugs In Development For Clostridium Difficle Infection
Table 34 Microbiome-based Drugs In Development For Clostridium Difficle Infection
Table 35 Microbiome-based Drugs In Development For Clostridium Difficle Infection
Table 36 Microbiome-based Drugs In Development For Recurrent Bacterial Vaginosis And Urinary Tract Infection
Table 37 Microbiome-based Drugs In Development For Skin Diseases
Table 38 Microbiome-based Drugs In Development For Skin Diseases
Table 39 Microbiota Associated With Celiac Disease
Table 40 Microbiome-based Drugs In Development For Celiac Disease
Table 41 Microbiome-based Drugs In Development For Urea Cycle Disorder
Table 42 Microbiome-based Drugs In Development For Non-alcoholic Steatohepatitis
Table 43 Microbiome-based Drugs In Development For Hepatic Encephalopathy
Table 44 Focus Areas For Microbiome Research Of Specific Diseases
Table 45 Microbiome Drug Development Approaches
Table 46 Investments In Microbiology
Table 47 U.S. Patents For C. Difficle Infection
Table 48 U.S. Patents On Microbiome-based Drugs For Irritable Bowel Syndrome
Table 49 U.S. Patents On Microbiome-based Drugs For Diabetes And Obesity
Table 50 U.S. Patents On Microbiome-based Drugs For Cancer
Table 51 U.S. Patents On Microbiome-based Drugs For Urea Cycle Disorders
Table 52 Venture Capital Investments In Microbiome Start-ups ($ Millions)
Table 53 Industry Collaborations In Microbiome-based Companies ($ Millions)
Table 54 Global Human Microbiome Market By Geography 2018-2022 ($ Million)
Table 55 Global Human Microbiome Market By Geography 2022-2026 ($ Million)
Table 56 North America Human Microbiome Market 2018-2022 ($ Million)
Table 57 North America Human Microbiome Market 2022-2026 ($ Million)
Table 58 Collective Programs By Cihr's On Human Microbiome In 2017
Table 59 Europe Human Microbiome Market 2018-2022 ($ Million)
Table 60 Europe Human Microbiome Market 2012-2026 ($ Million)
Table 61 Asia Pacific Human Microbiome Market 2018-2022 ($ Million)
Table 62 Asia Pacific Human Microbiome Market 2022-2026 ($ Million)
Table 63 Rest Of World Human Microbiome Market 2018-2022 ($ Million)
Table 64 Rest Of World Human Microbiome Market 2022-2026 ($ Million)
Figure List
Figure 1 Global Human Microbiome Market 2018-2026 ($ Million)
Figure 2 Estimated Number Of People With Chronic Conditions In United States
Figure 3 Global Human Microbiome Market In Drugs 2018-2026 ($ Million)
Figure 4 Global Human Microbiome Market In Drugs 2018-2026 ($ Million)
Figure 5 Global Human Microbiome Market In Probiotics 2018-2026 ($ Million)
Figure 6 Global Human Microbiome Market In Foods 2018-2026 ($ Million)
Figure 7 Global Human Microbiome Market In Prebiotics 2018-2026 ($ Million)
Figure 8 Global Human Microbiome Market In Medical Foods 2018-2026 ($ Million)
Figure 9 Global Human Microbiome Market In Diagnostic Device 2018-2026 ($ Million)
Figure 10 Global Human Microbiome Market In Drugs 2018-2026 ($ Million)
Figure 11 Global Human Microbiome Market In Other Products 2018-2026 ($ Million)
Figure 12 Global Human Microbiome Market In Cancer 2018-2026 ($ Million)
Figure 13 Global Human Microbiome Market In Obesity 2018-2026 ($ Million)
Figure 14 Global Human Microbiome Market In Type 2 Diabetes 2018-2026 ($ Million)
Figure 15 Global Human Microbiome Market In Ulcerative Colitis 2018-2026 ($ Million)
Figure 16 Global Human Microbiome Market In Crohn’s Disease 2018-2026 ($ Million)
Figure 17 Global Human Microbiome Market In C. Difficle Infection 2018-2026 ($ Million)
Figure 18 Global Human Microbiome Market In Lactose Intolerance 2018-2026 ($ Million)
Figure 19 Global Human Microbiome Market In Dental Caries 2018-2026 ($ Million)
Figure 20 Global Human Microbiome Market In Recurrent Bacterial Vaginosis And Uti 2018-2026 ($ Million)
Figure 21 Global Human Microbiome Market In Skin Disorders 2018-2026 ($ Million)
Figure 22 Microbes Involved In Healthy Facial Skin (Percent Microbes)
Figure 23 Global Human Microbiome Market In Hyperoxaluria 2018-2026 ($ Million)
Figure 24 Global Human Microbiome Market In Celiac Disease 2018-2026 ($ Million)
Figure 25 Global Human Microbiome Market In Urea Cycle Disorder 2018-2026 ($ Million)
Figure 26 Global Human Microbiome Market In Phenylketonuria 2018-2026 ($ Million)
Figure 27 Global Human Microbiome Market In Non-alcoholic Steatohepatitis 2018-2026 ($ Million)
Figure 28 Global Human Microbiome Market In Hepatic Encephalopathy 2018-2026 ($ Million)
Figure 29 Healthcare Expenditure In The U.S. 2015-2025 (% Of Gdp)
Figure 30 Research And Development Spending In The Life Science 2014-2016 ($ Billion)
Figure 31 Number Of Patents Granted For Worldwide Microbiome-based Drugs 2010-2017
Figure 32 North America Human Microbiome Market 2018-2026 ($ Million)
Figure 33 The U.S. Human Microbiome Market 2018-2026 ($ Million)
Figure 34 Canada Human Microbiome Market 2018-2026 ($ Million)
Figure 35 Europe Human Microbiome Market 2018-2026 ($ Million)
Figure 36 The United Kingdom Human Microbiome Market 2018-2026 ($ Million)
Figure 37 France Human Microbiome Market 2018-2026 ($ Million)
Figure 38 Germany Human Microbiome Market 2018-2026 ($ Million)
Figure 39 Italy Human Microbiome Market 2018-2026 ($ Million)
Figure 40 Spain Human Microbiome Market 2018-2026 ($ Million)
Figure 41 Rest Of Europe Human Microbiome Market 2018-2026 ($ Million)
Figure 42 Asia Pacific Human Microbiome Market 2018-2026 ($ Million)
Figure 43 China Human Microbiome Market 2018-2026 ($ Million)
Figure 44 India Human Microbiome Market 2018-2026 ($ Million)
Figure 45 Japan Human Microbiome Market 2018-2026 ($ Million)
Figure 46 South Korea Human Microbiome Market 2018-2026 ($ Million)
Figure 47 Australia Human Microbiome Market 2018-2026 ($ Million)
Figure 48 Rest Of Apac Human Microbiome Market 2018-2026 ($ Million)
Figure 49 Rest Of World Human Microbiome Market 2018-2026 ($ Million)
Figure 50 Latin America Human Microbiome Market 2018-2026 ($ Million)
Figure 51 Middle East & Africa Human Microbiome Market 2018-2026 ($ Million)
Figure 52 Market Share Analysis Of Global Human Microbiome Market 2017(%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report